AU2016335912B2 - Antibodies with improved stability to intestinal digestion - Google Patents

Antibodies with improved stability to intestinal digestion Download PDF

Info

Publication number
AU2016335912B2
AU2016335912B2 AU2016335912A AU2016335912A AU2016335912B2 AU 2016335912 B2 AU2016335912 B2 AU 2016335912B2 AU 2016335912 A AU2016335912 A AU 2016335912A AU 2016335912 A AU2016335912 A AU 2016335912A AU 2016335912 B2 AU2016335912 B2 AU 2016335912B2
Authority
AU
Australia
Prior art keywords
antibody
bovine
antibodies
domain
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016335912A
Other languages
English (en)
Other versions
AU2016335912A1 (en
Inventor
Randall Edward Burton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Circle33 LLC
Original Assignee
Circle33 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circle33 LLC filed Critical Circle33 LLC
Publication of AU2016335912A1 publication Critical patent/AU2016335912A1/en
Priority to AU2023216791A priority Critical patent/AU2023216791A1/en
Application granted granted Critical
Publication of AU2016335912B2 publication Critical patent/AU2016335912B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016335912A 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion Ceased AU2016335912B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023216791A AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237270P 2015-10-05 2015-10-05
US62/237,270 2015-10-05
PCT/US2016/054304 WO2017062253A2 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023216791A Division AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Publications (2)

Publication Number Publication Date
AU2016335912A1 AU2016335912A1 (en) 2018-05-24
AU2016335912B2 true AU2016335912B2 (en) 2023-08-31

Family

ID=58488349

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016335912A Ceased AU2016335912B2 (en) 2015-10-05 2016-09-29 Antibodies with improved stability to intestinal digestion
AU2023216791A Abandoned AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023216791A Abandoned AU2023216791A1 (en) 2015-10-05 2023-08-16 Antibodies with improved stability to intestinal digestion

Country Status (8)

Country Link
US (2) US11891440B2 (enExample)
EP (1) EP3359190A4 (enExample)
JP (2) JP7235287B2 (enExample)
AU (2) AU2016335912B2 (enExample)
BR (1) BR112018006953A2 (enExample)
CA (1) CA3039177A1 (enExample)
IL (1) IL258496A (enExample)
WO (1) WO2017062253A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019001896A (es) * 2016-08-15 2019-08-29 Univ Hokkaido Nat Univ Corp Anticuerpo anti-pd-l1.
WO2020123798A1 (en) * 2018-12-12 2020-06-18 President And Fellows Of Harvard College Bovine versions of fcmbl for the detection and treatment of bovine microbial infections
KR20230110297A (ko) * 2020-11-20 2023-07-21 조에티스 서비시즈 엘엘씨 소 항체 변이체
EP4695308A1 (en) * 2023-09-14 2026-02-18 Invitrogen BioServices India Private Limited Engineered antibodies and uses thereof
CN120209146B (zh) * 2025-03-31 2026-07-28 上海百英生物科技股份有限公司 一种包含非天然氨基酸修饰的Claudin 6抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US8647626B2 (en) * 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
WO2009046168A1 (en) * 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2494061B1 (en) * 2009-10-29 2017-01-25 Janssen Biotech, Inc. Antibody glycosylation variants
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
MX2013007527A (es) * 2010-12-27 2014-02-27 Japan Health Science Found Anticuerpo monoclonal que reconoce la proteina l2 de virus de papiloma humano y metodo para medir el titulo del anticuerpo neutralizante de vph utilizando el mismo.
WO2013019889A2 (en) * 2011-08-01 2013-02-07 Avaxia Biologics, Inc. Bovine polyclonal antibody specific for human tnf
AU2017313495B2 (en) * 2016-08-15 2023-09-07 Fuso Pharmaceutical Industries, Ltd. Anti-PD-1 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNIGHT, KL. et al., 'Genetic engineering of bovine lg. Construction and characterization of hapten-binding bovine/murine chimeric IgE, IgA, IgG1, IgG2, and IgG3 molecules', The Journal of Immunology. 1988, vol. 140, no. 10, pages 3654-3659 *

Also Published As

Publication number Publication date
IL258496A (en) 2018-05-31
WO2017062253A3 (en) 2017-05-11
CA3039177A1 (en) 2017-04-13
AU2023216791A1 (en) 2023-09-07
EP3359190A2 (en) 2018-08-15
US11891440B2 (en) 2024-02-06
EP3359190A4 (en) 2020-05-06
BR112018006953A2 (pt) 2018-10-23
JP2018537117A (ja) 2018-12-20
US20220073602A1 (en) 2022-03-10
AU2016335912A1 (en) 2018-05-24
JP2022185053A (ja) 2022-12-13
US20240067715A1 (en) 2024-02-29
WO2017062253A2 (en) 2017-04-13
JP7235287B2 (ja) 2023-03-08

Similar Documents

Publication Publication Date Title
US20240067715A1 (en) Antibodies with improved stability to intestinal digestion, polynucleotides thereof and methods of use thereof to treat disease
CN112513089A (zh) 抗cd73抗体、其抗原结合片段及应用
TW201837056A (zh) Ｂ７－ｈ３抗體、其抗原結合片段及其醫藥用途
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
US20190375839A1 (en) Tim-3 antibody, antigen binding fragment thereof, and medicinal uses thereof
CN113906053B (zh) 抗cea抗体及其应用
US20200216528A1 (en) Anti-il-22r antibodies
AU2023200779B2 (en) TGF-beta-RII binding proteins
TW201900213A (zh) 免疫球蛋白ａ陽性細胞的調節
CN113260632A (zh) 包含IgA抗体构建体的组合物和方法
US20220396615A1 (en) Anti-human il6 monoclonal antibodies, preparation method therefor and use thereof
TW202346594A (zh) 經修飾之抗體及其用途
CN118647631A (zh) 用抗trem2抗体治疗纤维化
TW202112813A (zh) 對lif具有專一性的結合分子及其用途
WO2022103871A1 (en) Therapeutic compositions for the treatment of covid-19
WO2013172379A1 (ja) 新規抗体及びその用途
HK40094429A (en) Tgf-beta-rii binding proteins
HK40045560A (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired